Skip to content

GLP-1 constipation: how common it is and what helps

Updated Sep 30, 2026. Numbers in brackets link to the source each fact comes from.

Constipation is a common side effect of GLP-1 medicines, and it behaves a little differently from nausea: on some labels it does not rise with the dose. On Zepbound, for example, it was reported by 17% of people on 5 mg and 11% on 15 mg in the weight trials [2]. Most of the time it is a nuisance that diet, fluids and activity can help with, but the labels also describe rare cases of blocked bowels.

How often it happened in the trials

The table compares each medicine with placebo, a dummy shot or pill taken by a comparison group. The Zepbound row counts constipation and hard stools together [3]. Column order comes from each label’s table header.

Medicine and trial group Placebo On the medicine
Zepbound 5, 10 and 15 mg, weight trials 5% 17%, 14%, 11% [1] [2]
Wegovy injection 2.4 mg, weight trials 11% 24% [4] [5]
Wegovy injection 7.2 mg trial (2.4 mg arm in brackets) 8% 20% (19%) [6] [7]
Foundayo 5.5, 9 and 17.2 mg, weight trials 9% 20%, 27%, 24% [8] [9]
Ozempic 0.5 and 1 mg, diabetes trials 1.5% 5%, 3.1% [10] [11]
Mounjaro 5, 10 and 15 mg, diabetes trials 1% 6%, 6%, 7% [12] [13]

In a separate heart outcomes trial of Mounjaro in people with type 2 diabetes and heart disease, constipation was reported by 13% [14]. The Wegovy tablet trial had side effects similar in type and frequency to the injection table [15].

These trials enrolled different people, so the rows do not rank the drugs. Full tables are on the pages for Zepbound, Wegovy, Foundayo, Ozempic and Mounjaro.

How long it lasts

The labels do not say. When the Zepbound label describes symptoms that eased after the dose-raising period, it names nausea, vomiting and diarrhea, not constipation [16]. The Mounjaro and Foundayo labels use the same short list [29] [30]. So there is no label basis for expecting constipation to fade on its own after a few weeks. If it continues, bring it up at your next check-in rather than waiting it out.

What helps, according to NIH

MedlinePlus and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) give general advice for constipation from any cause. None of it is written for GLP-1 medicines, and eating less overall can make some of it harder to follow.

  • Move. MedlinePlus suggests walking, swimming or other activity at least 3 or 4 times a week [18].
  • Drink. It suggests 8 to 10 cups of liquid a day, mostly water [19].
  • Add fiber slowly. Adding it too fast can cause bloating and gas [20]. NIDDK says adults generally need 22 to 34 grams a day, depending on age and sex [21].
  • Do not hold it in when you feel the urge to go [22].
  • Laxatives, short term, with advice. NIDDK says a health professional may recommend a laxative for a short time [23]. MedlinePlus says not to take one if you have severe stomach pain, nausea or vomiting, and not for more than 1 week without checking with your provider [24].
  • Ask about your other medicines. Some medicines and supplements cause constipation, and NIDDK says to talk with your doctor if you suspect one [25].

One source does write about GLP-1 treatment. A 2025 joint advisory from four obesity and nutrition groups (the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society) says constipation is common with weight loss and should be managed proactively, starting with enough fluids and fiber from food, though more is often needed [31]. If diet is not enough, it lists daily magnesium, fiber supplements or capsules and polyethylene glycol 3350, and says stool softeners can help avoid straining [32]. None of the GLP-1 labels recommends these products, so ask your prescriber or pharmacist which, if any, fits you.

When to call a doctor

MedlinePlus says to contact a provider if you have not had a bowel movement in 3 days, feel bloated or have stomach pain, are nauseated or vomiting, or see blood in your stool [26].

The labels add warnings specific to these medicines:

  • Blocked bowel. After Zepbound went on sale, reports came in of ileus (the gut stops moving), intestinal obstruction and severe constipation with fecal impaction. Because these reports are voluntary, the label says their frequency cannot be reliably estimated [17].
  • Severe stomach problems. Tell your provider about stomach problems that are severe or will not go away [27].
  • Pancreatitis. Stop the medicine and call right away for severe stomach pain that will not go away, with or without vomiting, sometimes spreading to the back [28].

Sources

  1. Adverse Reaction Placebo (N=958) % ZEPBOUND 5 mg (N=630) % ZEPBOUND 10 mg (N=948) % ZEPBOUND 15 mg (N=941) % dailymed.nlm.nih.gov, read Sep 27, 2026.
  2. Constipationb 5 17 14 11 dailymed.nlm.nih.gov, read Sep 27, 2026.
  3. b Includes constipation, feces hard. dailymed.nlm.nih.gov, read Sep 27, 2026.
  4. Placebo N=1,261 % WEGOVY Injection (2.4 mg Once Weekly) N=2,116 % dailymed.nlm.nih.gov, read Sep 27, 2026.
  5. Constipation 11 24 dailymed.nlm.nih.gov, read Sep 27, 2026.
  6. Placebo N=303 % WEGOVY Injection (2.4 mg Once Weekly) N=304 % WEGOVY Injection (7.2 mg Once Weekly) N=1,311 % dailymed.nlm.nih.gov, read Sep 27, 2026.
  7. Constipation 8 19 20 dailymed.nlm.nih.gov, read Sep 27, 2026.
  8. Adverse Reaction Placebo (N=1,576) % FOUNDAYO 5.5 mg once daily (N=1,051) % FOUNDAYO 9 mg once daily (N=1,055) % FOUNDAYO 17.2 mg once daily (N=1,049) % dailymed.nlm.nih.gov, read Sep 27, 2026.
  9. Constipation 9 20 27 24 dailymed.nlm.nih.gov, read Sep 27, 2026.
  10. Adverse Reaction Placebo (N=262) % OZEMPIC 0.5 mg (N=260) % OZEMPIC 1 mg (N=261) % dailymed.nlm.nih.gov, read Sep 27, 2026.
  11. Constipation 1.5 5 3.1 dailymed.nlm.nih.gov, read Sep 27, 2026.
  12. Adverse Reaction Placebo (N=235) % MOUNJARO 5 mg (N=237) % MOUNJARO 10 mg (N=240) % MOUNJARO 15 mg (N=241) % dailymed.nlm.nih.gov, read Sep 27, 2026.
  13. Constipation 1 6 6 7 dailymed.nlm.nih.gov, read Sep 27, 2026.
  14. In a CV outcomes trial of 6,647 adults with type 2 diabetes mellitus and established CV disease exposed to MOUNJARO, adverse reactions reported with MOUNJARO were similar with the exception of dysesthesia (0.7%), decreased appetite (17%), constipation (13%), vomiting (12%), abdominal pain (10%), and fatigue (10%) dailymed.nlm.nih.gov, read Sep 27, 2026.
  15. In the clinical trial with WEGOVY 25 mg tablets, the types and frequency of common adverse reactions were similar to those listed in Table 3. dailymed.nlm.nih.gov, read Sep 27, 2026.
  16. The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time. dailymed.nlm.nih.gov, read Sep 27, 2026.
  17. The following adverse reactions have been reported during post-approval use of tirzepatide, the active ingredient in ZEPBOUND. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure. Gastrointestinal: acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction dailymed.nlm.nih.gov, read Sep 27, 2026.
  18. Exercise regularly. Drink more water and eat more fiber . Try to walk, swim, or do something active at least 3 or 4 times a week. medlineplus.gov, read Sep 27, 2026.
  19. Drink 8 to 10 cups (2 to 2.5 L) of liquids, particularly water, every day. medlineplus.gov, read Sep 27, 2026.
  20. Add foods with fiber to your diet slowly, because eating more fiber can cause bloating and gas. medlineplus.gov, read Sep 27, 2026.
  21. Depending on your age and sex, adults should get 22 to 34 grams of fiber a day. niddk.nih.gov, read Sep 27, 2026.
  22. If you feel the urge to go to the bathroom, go. Do not wait or hold it in. medlineplus.gov, read Sep 27, 2026.
  23. Your health care professional may recommend using a laxative for a short time. niddk.nih.gov, read Sep 27, 2026.
  24. Do not take it if you have severe stomach pain, nausea, or vomiting. Do not take it for more than 1 week without consulting your provider. medlineplus.gov, read Sep 27, 2026.
  25. If you think certain medicines or dietary supplements are causing your constipation, talk with your doctor. niddk.nih.gov, read Sep 27, 2026.
  26. Have not had a bowel movement in 3 days Are bloated or have pain in your stomach Have nausea or throw up Have blood in your stool medlineplus.gov, read Sep 27, 2026.
  27. Stomach problems, sometimes severe, have been reported in people who use ZEPBOUND. Tell your healthcare provider if you have stomach problems that are severe or will not go away. dailymed.nlm.nih.gov, read Sep 27, 2026.
  28. Stop using ZEPBOUND and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back. dailymed.nlm.nih.gov, read Sep 27, 2026.
  29. The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation and decreased over time. dailymed.nlm.nih.gov, read Sep 27, 2026.
  30. The incidence of nausea, vomiting, and diarrhea was higher during the FOUNDAYO dosage escalation period and decreased over time. dailymed.nlm.nih.gov, read Sep 27, 2026.
  31. Constipation is common with weight loss and should be managed proactively. Extended constipation can also lead to reactive diarrhea. Adequate fluids and fiber from foods should be encouraged, although additional strategies are often required. pmc.ncbi.nlm.nih.gov, read Sep 28, 2026.
  32. If dietary strategies are insufficient, other therapies include daily magnesium supplementation, titrated to keep bowel movements regular. Magnesium citrate is effective and well-tolerated, and powdered forms permit customized dosing. Fiber supplements or capsules and Polyethylene Glycol 3350 may also be beneficial. Stool softeners may also be helpful in avoiding straining. pmc.ncbi.nlm.nih.gov, read Sep 28, 2026.

This page reports what official sources say; it is not medical advice. Medical disclaimer.